Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.

[1]  I. Petersen,et al.  Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma , 2011, Journal of Cancer Research and Clinical Oncology.

[2]  R. Advani,et al.  Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B‐cell lymphoma treated with R‐CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E‐IPI) , 2010, British journal of haematology.

[3]  B. Coiffier,et al.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.

[4]  S. Pal,et al.  Evaluating the Older Patient with Cancer: Understanding Frailty and the Geriatric Assessment , 2010, CA: a cancer journal for clinicians.

[5]  I. Flinn,et al.  Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium. , 2010, Clinical lymphoma, myeloma & leukemia.

[6]  G. Rossi,et al.  A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy , 2009, Cancer.

[7]  J. Leonard,et al.  Targeted treatment and new agents in diffuse large B-cell lymphoma. , 2008, Seminars in hematology.

[8]  Carla L Graf,et al.  The Lawton Instrumental Activities of Daily Living Scale , 2008, The American journal of nursing.

[9]  Markus Loeffler,et al.  Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.

[10]  S. Hee,et al.  Performance status is the single most important prognostic factor in lymphoma patients aged greater than 75 overriding other prognostic factors such as histology , 2008, Leukemia & lymphoma.

[11]  J. Armitage.  Is lymphoma occurring in the elderly the same disease? , 2008, Leukemia & lymphoma.

[12]  M. Tan,et al.  Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab , 2008, Leukemia & lymphoma.

[13]  M. Extermann,et al.  Comprehensive geriatric assessment for older patients with cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Randy D Gascoyne,et al.  Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  O. Bairey,et al.  Non-Hodgkin's lymphoma in patients 80 years of age or older. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Dirk Hasenclever,et al.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. , 2004, Blood.

[18]  H. Kerl,et al.  Large B-Cell Lymphoma, Leg Type , 2004 .

[19]  E. Noordijk,et al.  Non-Hodgkin's lymphoma in the elderly , 2003, Annals of Hematology.

[20]  P. Sonneveld,et al.  CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  John Myhre,et al.  CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. , 2003, Blood.

[22]  I. Ellis,et al.  A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[24]  V. Morrison,et al.  The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. , 2001, Clinical lymphoma.

[25]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  H. Gómez,et al.  Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Blay,et al.  Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[29]  F. d'Amore,et al.  Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-Study Group. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  F. d'Amore,et al.  Original article: Non-Hodgkin's lymphoma in the elderly A study of 602 patients aged 70 or older from a Danish population-based registry , 1992 .

[31]  J. Armitage,et al.  Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  B. Coiffier,et al.  Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen. , 1989, Blood.

[33]  B. Pégourié,et al.  Non‐Hodgkin's malignant lymphomas in patients older than 80 70 Cases , 1988, Cancer.

[34]  J. Armitage,et al.  Aggressive Chemotherapy for Diffuse Histiocytic Lymphoma in the Elderly: Increased Complications with Advancing Age , 1984, Journal of the American Geriatrics Society.

[35]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[36]  M. Lawton,et al.  Assessment of older people: self-maintaining and instrumental activities of daily living. , 1969, The Gerontologist.

[37]  R. Houot,et al.  Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  D. Weisenburger,et al.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.

[39]  F. Jardin,et al.  Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old. , 2005, Haematologica.

[40]  W. Hryniuk.  The importance of dose intensity in the outcome of chemotherapy. , 1988, Important advances in oncology.

[41]  Hryniuk Wm.  The importance of dose intensity in the outcome of chemotherapy. , 1988 .